Roche: positive results for rare nervous disease drug
(CercleFinance.com) - Chugai, the Japanese unit of Swiss drugmaker Roche, said that a late-stage study has showed that its drug satralizumab significantly reduces the risk of relapse in a rare, debilitating auto-immune disease of the central nervous system.
In the phase III study to evaluate the efficacy and safety of the investigational antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD), satralizumab reduced the risk of relapse by 55% in the overall population, Chugai said.
Chugai now plans to collaborate with Roche to file global regulatory applications this year, so that it can bring satralizumab to the market.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
In the phase III study to evaluate the efficacy and safety of the investigational antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD), satralizumab reduced the risk of relapse by 55% in the overall population, Chugai said.
Chugai now plans to collaborate with Roche to file global regulatory applications this year, so that it can bring satralizumab to the market.
Copyright (c) 2019 CercleFinance.com. All rights reserved.